Anti-CRISPR technology is becoming more prevalent now
Antonio Regalado, 19, (Antonio Regalado, 5-2-2019, MIT Technology Review, The search for the kryptonite that can stop CRISPR, https://www.technologyreview.com/2019/05/02/65813/the-search-for-the-kryptonite-that-can-stop-crispr/, 6-28-2022) SCade
Anti-CRISPR By the time Doudna drafted her proposal to DARPA, other scientists already had one big clue for how to stop CRISPR. In the ancient struggle between bacteria and the viruses called phage that infect them, phage had developed their own antidotes to CRISPR. In fact, their genomes, it’s been found, harbor the ability to produce what is essentially CRISPR kryptonite—small proteins exquisitely tuned by evolution to disable the gene-editing tool. Scientists call these molecules “anti-CRISPRs.” The first anti-CRISPRs were discovered in 2013 by a student at the University of Toronto named Joseph Bondy-Denomy. “It was serendipity. We stumbled onto the fact that some phages seemed to be resistant to CRISPR. When we put the phage into a cell, the bacteria couldn’t protect itself,” says Bondy-Denomy, now a professor at the University of California, San Francisco. He quickly zeroed in on one of the virus’s 50 or so genes as the reason. “We thought, wow, maybe this is turning off CRISPR.” The number of labs studying such defenses is smaller than the number working with CRISPR. But anti-CRISPR is becoming a booming field in its own right. More than 40 anti-CRISPR proteins have already been found, many by Doudna’s lab. Other teams are having early success locating conventional chemicals that can inhibit CRISPR as well. Today, Amit Choudhary of Harvard Medical School, in Boston, also with funding from DARPA, reported he had found two drugs that prevent gene-editing when mixed with human cells. “The hallmark of any powerful technology is control,” says Choudhary. “It’s that simple.” Researchers like Bondy-Denomy believe anti-CRISPRs could have a role in improving future gene-editing treatments, by giving researchers more precise control. For instance, a team in Germany recently showed if they combined CRISPR and anti-CRISPR, they could create an editor that will change DNA only in liver cells, not neurons or muscle. Another application being studied is whether anti-CRISPR could create a safeguard against “gene drives.” The Bill & Melinda Gates Foundation is backing the development of a CRISPR tool that will spread though wild mosquitoes, causing their populations to crash, with the idea of preventing malaria. Others want to develop such gene drives in mice, so they can eradicate the rodents from islands without using poison. But what if these experiments go haywire and lead to an extinction? Researchers think they can create organisms with anti-CRISPR programmed into their genomes so they’re immune. In an initial proof of principle, scientists in Kansas last year engineered yeast cells with anti-CRISPR to resist a gene drive. “If some North Korean lab comes at you with a gene drive to wipe out an economically important crop, you could have a transgenic crop that [is resistant]. That is the drawing board scenario,” says Erik Sontheimer of the University of Massachusetts Medical School.